未治疗慢性乙型肝炎不确定期的自然史与肝细胞癌风险
这项回顾性队列研究纳入3366例未治疗非肝硬化慢性乙型肝炎患者,随访平均12.5年。基线时38.7%处于不确定期,其中52.7%持续不确定,21.7%转为免疫活动期。持续不确定期患者10年肝细胞癌累积发生率4.6%显著高于非活动期的0.5%, adjusted HR为14.1;年龄≥45岁与肝癌风险独立相关(aHR 18.4)。
要点
- 近40%未治疗非肝硬化CHB患者基线处于不确定期。
- 持续不确定期10年HCC累积发生率4.6%,显著高于非活动期0.5%。
- 持续不确定期且年龄≥45岁者HCC风险显著升高(aHR 18.4)。
核心结论
- 持续不确定期CHB患者的HCC风险是持续非活动期的14倍。
- 持续不确定期且年龄≥45岁与HCC风险独立相关(aHR 18.4)。
研究设计与样本
- 回顾性队列研究,纳入3366例成人未治疗非肝硬化CHB患者,来自5家美国诊所和7个台湾乡镇。
- 入组前至少有1年连续实验室数据,平均随访12.5年。
- 基线及随访期间依据AASLD 2018指南确定临床分期。
主要发现
- 基线时1303例(38.7%)处于不确定期。
- 随访至第10年,686例(52.7%)仍为不确定期,283例(21.7%)转为免疫活动期。
- 持续不确定期 vs 持续非活动期:10年HCC累积发生率4.6% vs 0.5%(P < .0001)。
- 持续不确定期 vs 持续非活动期:HCC调整风险比14.1(P = .03)。
- 持续不确定期中,年龄≥45岁与HCC独立相关(aHR 18.4;P = .005)。
临床怎么用
- 对未治疗非肝硬化CHB患者应识别不确定期,尤其年龄≥45岁者需加强HCC监测。
- 持续不确定期患者HCC风险显著高于非活动期,应考虑更密切随访。
局限性
- 原文未明确报告回顾性设计之外的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many patients with chronic hepatitis B (CHB) may not conform to any of the defined phases and hence are classified as indeterminate. We aimed to characterize the baseline prevalence of indeterminate patients and their natural history, phase transition, and hepatocellular carcinoma (HCC) risk. METHODS: This was a retrospective cohort study of 3366 adult untreated noncirrhotic CHB patients seen at 5 US clinics and 7 Taiwanese townships who had at least 1 year of serial laboratory data before enrollment with a mean follow-up period of 12.5 years. Patients' clinical phases were determined at baseline and through serial data during follow-up evaluation, based on the American Association for the Study of Liver Diseases 2018 guidance. RESULTS: At baseline, 1303 (38.7%) patients were in the indeterminate phase. By up to year 10 of follow-up evaluation, 686 patients (52.7%) remained indeterminate, while 283 patients (21.7%) became immune active. Compared with patients who remained inactive, patients who remained indeterminate had a higher 10-year cumulative HCC incidence (4.6% vs 0.5%; P < .0001) and adjusted hazard ratio for HCC of 14.1 (P = .03). Among patients who remained indeterminate, age 45 years and older (adjusted hazard ratio, 18.4; P = .005) was associated independently with HCC development. CONCLUSIONS: Nearly 40% of patients had indeterminate CHB phase. Of these, half remained indeterminate and one-fifth transitioned to the immune active phase. HCC risk in persistently indeterminate CHB was 14 times higher than inactive CHB. Among persistently indeterminate CHB patients, age 45 years and older was associated with an 18 times higher risk for HCC development. Further studies are needed to evaluate the potential benefit of antiviral therapy for indeterminate patients, especially in the older subgroup.
引用
- Huang DQ, Li X, Le MH, et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol. 2021. PMID: 33465482. doi:10.1016/j.cgh.2021.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。